Cholesterol level and symptomatic hemorrhagic transformation after ischemic stroke thrombolysis

Neurology

Volumn 68, Issue 10, 2007, Pages 737-742

  Bang, O Y ^a   Saver, J L ^b   Liebeskind, D S ^b   Starkman, S ^b   Villablanca, P ^b   Salamon, N ^b   Buck, B ^b   Ali, L ^b   Restrepo, L ^b   Vinuela, F ^b   Duckwiler, G ^b   Jahan, R ^b   Razinia, T ^b   Ovbiagele, B ^b,c  

^a Sungkyunkwan University   (South Korea)

^b UCLA MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; FIBRINOLYTIC AGENT; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TISSUE PLASMINOGEN ACTIVATOR;

AGED; ARTICLE; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CONFIDENCE INTERVAL; CONTROLLED STUDY; COVARIANCE; DISEASE ASSOCIATION; DRUG USE; EMBOLECTOMY; FEMALE; GLUCOSE BLOOD LEVEL; HEALTH CARE ORGANIZATION; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; HYPOCHOLESTEROLEMIA; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RATING SCALE; RECANALIZATION; REGISTER; RISK ASSESSMENT; SCORING SYSTEM; SEX DIFFERENCE; SEX RATIO; SMOKING; TREATMENT OUTCOME; UNIVARIATE ANALYSIS; CHEMICALLY INDUCED DISORDER; CHI SQUARE DISTRIBUTION; COMPARATIVE STUDY; EVALUATION; FIBRINOLYTIC THERAPY; HOSPITALIZATION; METABOLISM; METHODOLOGY; MIDDLE AGED; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICAL MODEL;

AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; CEREBRAL HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CHI-SQUARE DISTRIBUTION; CHOLESTEROL; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SEX FACTORS; SMOKING; THROMBOLYTIC THERAPY;

EID: 33947517351     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000252799.64165.d5     Document Type: Article

References (38)

1. Kidwell CS, Saver JL, Carneado J, et al. Predictors of hemorrhagic transformation in patients receiving intra-arterial thrombolysis. Stroke 2002;33:717-724.
2. Fisher M, Adams RD. Observations on brain embolism with special reference to the mechanism of hemorrhagic infarction. J Neuropathol Exp Neurol 1951;10:92-94.
3. The NINDS t-PA Stroke Study Group. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. Stroke 1997;28:2109-2118.
4. Furlan A, Higashida R, Wechsler L, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II Study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism JAMA 1999;282:2003-2011.
5. Smith WS, Sung G, Starkman S, et al. Safety and efficacy of mechanical embolectomy in acute ischemic stroke: results of the Merci trial. Stroke 2005;36:1432-1438.
6. Demchuk AM, Morgenstern LB, Krieger DW, et al. Serum glucose level and diabetes predict tissue plasminogen activator-related intracerebral hemorrhage in acute ischemic stroke. Stroke 1999;30:34-39.
7. Kase CS, Furlan AJ, Wechsler LR, et al. Cerebral hemorrhage after intra-arterial thrombolysis for ischemic stroke: The PROACT II Trial. Neurology 2001;57:1603-1610.
8. Goldstein LB, Adams R, Alberts MJ, et al. Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: the American Academy of Neurology affirms the value of this guideline. Stroke 2006;37:1583-1633.
9. Amarenco P, Bogousslavsky J, Callahan A3rd, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006;355:549-559.
10. Iso H, Jacobs DR Jr, Wentworth D, Neaton JD, Cohen JD. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med 1989;320:904-910.
11. Eastern Stroke and Coronary Heart Disease Collaborative Research Group. Blood pressure, cholesterol, and stroke in eastern Asia. Lancet 1998;352:1801-1807.
12. Thrift A, McNeil J, Donnan G. Reduced frequency of high cholesterol levels among patients with intracerebral haemorrhage. J Clin Neurosci 2002;9:376-380.
13. Tanaka H, Ueda Y, Hayashi M, et al. Risk factors for cerebral hemorrhage and cerebral infarction in a Japanese rural community. Stroke 1982;13:62-73.
14. Moonis M, Kane K, Schwiderski U, Sandage BW, Fisher M. HMG-CoA reductase inhibitors improve acute ischemic stroke outcome. Stroke 2005;36:1298-1300.
15. Elkind MS, Flint AC, Sciacca RR, Sacco RL. Lipid-lowering agent use at ischemic stroke onset is associated with decreased mortality. Neurology 2005;65:253-258.
16. Greisenegger S, Mullner M, Tentschert S, Lang W, Lalouschek W. Effect of pretreatment with statins on the severity of acute ischemic cerebrovascular events. J Neurol Sci 2004;221:5-10.
17. Seyfried D, Han Y, Lu D, Chen J, Bydon A, Chopp M. Improvement in neurological outcome after administration of atorvastatin following experimental intracerebral hemorrhage in rats. J Neurosurg 2004;101:104-107.
18. Jung KH, Chu K, Jeong SW, et al. HMG-CoA reductase inhibitor, atorvastatin, promotes sensorimotor recovery, suppressing acute inflammatory reaction after experimental intracerebral hemorrhage. Stroke 2004;35:1744-1749.
19. Woo D, Kissela BM, Khoury JC, et al. Hypercholesterolemia, HMG-CoA reductase inhibitors, and risk of intracerebral hemorrhage: a case-control study. Stroke 2004;35:1360-1364.
20. Brown DL, Johnston KC, Wagner DP, Haley EC Jr . Predicting major neurological improvement with intravenous recombinant tissue plasminogen activator treatment of stroke. Stroke 2004;35:147-150.
21. Lee LJ, Kidwell CS, Alger J, Starkman S, Saver JL. Impact on stroke subtype diagnosis of early diffusion-weighted magnetic resonance imaging and magnetic resonance angiography. Stroke 2000;31:1081-1089.
22. Kargman DE, Tuck C, Berglund L, et al. Lipid and lipoprotein levels remain stable in acute ischemic stroke: the Northern Manhattan Stroke Study. Atherosclerosis 1998;139:391-399.
23. Gore JM, Goldberg RJ, Matsumoto AS, Castelli WP, McNamara PM, Dalen JE. Validity of serum total cholesterol level obtained within 24 hours of acute myocardial infarction. Am J Cardiol 1984;54:722-725.
24. Ovbiagele B, Saver JL, Fredieu A, et al. PROTECT: a coordinated stroke treatment program to prevent recurrent thromboembolic events. Neurology 2004;63:1217-1222.
25. TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) Trial. Phase I findings. N Engl J Med 1985;312:932-936.
26. Ebrahim S, Sung J, Song YM, Ferrer RL, Lawlor DA, Smith GD. Serum cholesterol, haemorrhagic stroke, ischaemic stroke, and myocardial infarction: Korean National Health System prospective cohort study. Br Med J 2006.
27. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
28. Collins R, Armitage J, Parish S, Sleight P, Peto R. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004;363:757-767.
29. Lee SH, Bae HJ, Yoon BW, Kim H, Kim DE, Roh JK. Low concentration of serum total cholesterol is associated with multifocal signal loss lesions on gradient-echo magnetic resonance imaging: analysis of risk factors for multifocal signal loss lesions. Stroke 2002;33:2845-2849.
30. Ooneda G, Yoshida Y, Suzuki K, et al. Smooth muscle cells in the development of plasmatic arterionecrosis, arteriosclerosis, and arterial contraction. Blood Vessels 1978;15:148-156.
31. Larrue V, von Kummer RR, Muller A, Bluhmki E. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke 2001;32:438-441.
32. Tanne D, Kasner SE, Demchuk AM, et al. Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the Multicenter rt-PA Stroke Survey. Circulation 2002;105:1679-1685.
33. Hemorrhage in the Interventional Management of Stroke Study. Stroke 2006;37:847-851.
34. Thrift AG, McNeil JJ, Forbes A, Donnan GA. Three important sub-groups of hypertensive persons at greater risk of intracerebral hemorrhage. Melbourne Risk Factor Study Group. Hypertension 1998;31:1223-1229.
35. Kurth T, Kase CS, Berger K, Schaeffner ES, Buring JE, Gaziano JM. Smoking and the risk of hemorrhagic stroke in men. Stroke 2003;34:1151-1155.
36. Kurth T, Kase CS, Berger K, Gaziano JM, Cook NR, Buring JE. Smoking and risk of hemorrhagic stroke in women. Stroke 2003;34:2792-2795.
37. Ruiz-Bailen M, Brea-Salvago JF, de Hoyos EA, et al. Post-thrombolysis intracerebral hemorrhage: data from the Spanish Register ARIAM. Crit Care Med 2005;33:1829-1838.
38. Segal AZ, Chiu RI, Eggleston-Sexton PM, Beiser A, Greenberg SM. Low cholesterol as a risk factor for primary intracerebral hemorrhage: a case-control study. Neuroepidemiology 1999;18:185-193.